The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the results of a Phase II study combining linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma. Prof. Dimopoulos reports encouraging safety and efficacy, warranting further investigation of this combination. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
